{"id":34956,"topic":"peptides","source":"生物谷","title":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 - 生物谷","url":"https://news.bioon.com/article/114990434660.html","url_hash":"81f6e47d11b352dca0f5cef89b624feaa53035f0","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBwOTllWlFaVXpfT0dSaUJBNWs5ZUFtbThsNFJfXy1OUVRDamhlQ2Z0NExFQjhMbGtPRE1fLWVmQURQbFhST1NfS2RaOERWNFl2emlPSXdWWll1RG5X?oc=5\" target=\"_blank\">Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物谷</font>","content":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)01375-3.\n版权声明 本网站所有注明“来源：生物谷”或“来源：bioon”的文字、图片和音视频资料，版权均属于生物谷网站所有。非经授权，任何媒体、网站或个人不得转载，否则将追究法律责任。取得书面授权转载时，须注明“来源：生物谷”。其它来源的文章系转载文章，本网所有转载文章系出于传递更多信息之目的，转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。","image_url":null,"lang":"zh","published_at":"2025-10-28T07:00:00+00:00","fetched_at":"2026-07-13T01:15:12+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025).","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://news.bioon.com/article/114990434660.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 849 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":849,"summary_length":626,"usable_text_length":849,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":849,"summary_length":626}},"news_item":{"id":34956,"canonical_url":"https://news.bioon.com/article/114990434660.html","source_url":"https://news.bioon.com/article/114990434660.html","title":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 - 生物谷","source_name":"生物谷","author":null,"published_at":"2025-10-28T07:00:00+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBwOTllWlFaVXpfT0dSaUJBNWs5ZUFtbThsNFJfXy1OUVRDamhlQ2Z0NExFQjhMbGtPRE1fLWVmQURQbFhST1NfS2RaOERWNFl2emlPSXdWWll1RG5X?oc=5\" target=\"_blank\">Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物谷</font>","full_text":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)01375-3.\n版权声明 本网站所有注明“来源：生物谷”或“来源：bioon”的文字、图片和音视频资料，版权均属于生物谷网站所有。非经授权，任何媒体、网站或个人不得转载，否则将追究法律责任。取得书面授权转载时，须注明“来源：生物谷”。其它来源的文章系转载文章，本网所有转载文章系出于传递更多信息之目的，转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。","excerpt":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025).","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 849 characters.","diagnostics_url":"/api/diagnose?url=https%3A//news.bioon.com/article/114990434660.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 849 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":849,"summary_length":626,"usable_text_length":849,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":849,"summary_length":626}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 - 生物谷","url":"https://news.bioon.com/article/114990434660.html","summary":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025).","source":"生物谷","date":"2025-10-28T07:00:00+00:00","content":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)01375-3.\n版权声明 本网站所有注明“来源：生物谷”或“来源：bioon”的文字、图片和音视频资料，版权均属于生物谷网站所有。非经授权，任何媒体、网站或个人不得转载，否则将追究法律责任。取得书面授权转载时，须注明“来源：生物谷”。其它来源的文章系转载文章，本网所有转载文章系出于传递更多信息之目的，转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//news.bioon.com/article/114990434660.html","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 849 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 849 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":849,"summary_length":626,"usable_text_length":849,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":849,"summary_length":626}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/34956","export_markdown":"/api/items/34956/export?format=markdown","export_json":"/api/items/34956/export?format=json","diagnose":"/api/diagnose?url=https%3A//news.bioon.com/article/114990434660.html"},"formats":{"full":{"id":34956,"title":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 - 生物谷","url":"https://news.bioon.com/article/114990434660.html","source":"生物谷","author":null,"published_at":"2025-10-28T07:00:00+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025).","full_text":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)01375-3.\n版权声明 本网站所有注明“来源：生物谷”或“来源：bioon”的文字、图片和音视频资料，版权均属于生物谷网站所有。非经授权，任何媒体、网站或个人不得转载，否则将追究法律责任。取得书面授权转载时，须注明“来源：生物谷”。其它来源的文章系转载文章，本网所有转载文章系出于传递更多信息之目的，转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 849 characters.","diagnostics_url":"/api/diagnose?url=https%3A//news.bioon.com/article/114990434660.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 849 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":849,"summary_length":626,"usable_text_length":849,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":849,"summary_length":626}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 849 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":849,"summary_length":626,"usable_text_length":849,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":849,"summary_length":626}},"actions":{"read":"/item/34956","export_markdown":"/api/items/34956/export?format=markdown","export_json":"/api/items/34956/export?format=json","diagnose":"/api/diagnose?url=https%3A//news.bioon.com/article/114990434660.html"}},"digest":{"id":34956,"title":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 - 生物谷","url":"https://news.bioon.com/article/114990434660.html","source":"生物谷","topic":"peptides","published_at":"2025-10-28T07:00:00+00:00","excerpt":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 来源：生物谷原创 2025-10-28 10:49 司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。 近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 849 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 - 生物谷","subtitle":"生物谷 · 2025-10-28","summary":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 来源：生物谷原创 2025-10-28 10:49 司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。 近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名…","badges":["quality:high"],"links":{"read":"/item/34956","original":"https://news.bioon.com/article/114990434660.html","diagnose":"/api/diagnose?url=https%3A//news.bioon.com/article/114990434660.html"},"quality_warning":null},"export":{"title":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制 - 生物谷","url":"https://news.bioon.com/article/114990434660.html","summary":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025).","source":"生物谷","date":"2025-10-28T07:00:00+00:00","content":"Lancet：不只为减肥！司美格鲁肽护心不靠减重，BMI27也受益，三分之二益处藏着这些关键机制\n来源：生物谷原创 2025-10-28 10:49\n司美格鲁肽防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。\n近年爆火的 “减肥针”semaglutide（司美格鲁肽，商品名 Wegovy/Ozempic），早已不止是 “体重管理工具”——伦敦大学学院 John Deanfield 教授团队在《柳叶刀》发表的最新研究（基于 SELECT 试验）颠覆认知：这种药物预防心脏病发作、中风等主要不良心血管事件（MACE）的效果，和服药后减了多少体重无关，哪怕是 BMI 仅 27 的 “略超重” 人群，也能和重度肥胖者（BMI≥40）获得同等保护。更意外的是，腰围缩小仅能解释三分之一的心脏益处，剩下三分之二的保护机制，藏在抗炎、护血管等 “非减重” 路径里。\n参考文献：\nJohn Deanfield et al, Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet (2025). DOI: 10.1016/S0140-6736(25)01375-3.\n版权声明 本网站所有注明“来源：生物谷”或“来源：bioon”的文字、图片和音视频资料，版权均属于生物谷网站所有。非经授权，任何媒体、网站或个人不得转载，否则将追究法律责任。取得书面授权转载时，须注明“来源：生物谷”。其它来源的文章系转载文章，本网所有转载文章系出于传递更多信息之目的，转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//news.bioon.com/article/114990434660.html","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 849 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 849 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":849,"summary_length":626,"usable_text_length":849,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":849,"summary_length":626}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}